Elicera Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Elicera Therapeutics is Jamal El-Mosleh, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. bezit rechtstreeks 8.39% van de aandelen van het bedrijf, ter waarde SEK 5.02M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.8 jaar.

Belangrijke informatie

Jamal El-Mosleh

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.8yrs
Eigendom CEO	8.4%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

CEO

Jamal El-Mosleh (43 yo)

4.8yrs

Tenure

Mr. Jamal El-Mosleh, M.Sc., is Co-Founder at Elicera Therapeutics AB (publ) and has been its CEO since 2020. He was a Director of Elypta AB since 2016 until September 2020. Mr. El-Mosleh served as Chief Ex...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jamal El-Mosleh	CEO & Co-Founder	4.8yrs	geen gegevens	8.39% SEK 5.0m
Magnus Essand	Chief Science Officer	4.8yrs	geen gegevens	9.6% SEK 5.7m
Di Yu	Co-Founder & Head of Transitional Research	no data	geen gegevens	9.76% SEK 5.8m
Ingvar Karlsson	Chief Financial Officer	3.8yrs	geen gegevens	0.10% SEK 61.4k
Anna Gultekin	Head of Regulatory Affairs	1.8yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ELIC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Magnus Essand	Chief Science Officer	10.8yrs	geen gegevens	9.6% SEK 5.7m
Margareth Jorvid	Independent Director	4.8yrs	geen gegevens	0.20% SEK 117.0k
Agneta Edberg	Independent Chairman	4.8yrs	geen gegevens	0.34% SEK 205.1k
Christina Herder	Independent Director	4.8yrs	geen gegevens	0.16% SEK 96.3k
Sharon Longhurst	Independent Director	less than a year	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ELIC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Elicera Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Elicera Therapeutics Includes the First Patient in the Phase I/II Clinical Study Carma Targeting B-Cell Lymphoma

Elicera Therapeutics AB (publ) Enrolls the Last Patient in the Clinical Phase I/II-Trial with Oncolytic Virus ELC-100

New major risk - Financial position

Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd